Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study
Open Access
- 31 December 2015
- journal article
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 2 (1) , e000021
Abstract
Objective Treatment of severe ulcerative colitis (UC) is challenging. Although the efficacy of tacrolimus (TAC) and infliximab (IFX) have been evaluated in patients with severe UC, the safety and efficacy levels of sequential therapies (TAC→IFX/IFX→TAC) in these patients remain unclear. The aim of this study was to assess short-term and long-term outcomes in patients with severe UC treated with TAC and IFX. Methods From October 2001 to February 2014, 29 patients with consecutive severe UC treated with TAC or IFX were retrospectively evaluated. Median follow-up duration was 27 months (range 0.5–118 months). The primary end point was short-term outcomes at 8 weeks after induction of TAC (TAC group, n=22) or IFX (IFX group, n=7). The secondary end point included long-term outcomes and colectomy-free survival. The clinical response was evaluated based on a partial Mayo score. Results The clinical remission (CR) rate at 8 weeks in the TAC and IFX groups was 63.6% and 71.4%, respectively. In 13 of the 29 patients (10 in the TAC group, 3 in the IFX group), sequential therapies were used in their clinical courses. In 9 of these 13 patients (6 in the TAC group, 3 in the IFX group), CR was achieved and maintained by sequential therapies. Overall cumulative colectomy-free survival was 79.3% at 118 months. Conclusions TAC and IFX had similar effects on remission induction in patients with severely active UC. Sequential therapies could rescue patients with UC who failed initial treatment with TAC or IFX. In clinical practice, sequential therapies might be deliberately performed.Keywords
This publication has 39 references indexed in Scilit:
- Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trialThe Lancet, 2012
- Cytomegalovirus Load in Inflamed Intestinal Tissue Is Predictive of Resistance to Immunosuppressive Therapy in Ulcerative ColitisAmerican Journal of Gastroenterology, 2011
- Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative ColitisInflammatory Bowel Diseases, 2008
- Long‐term effect of tacrolimus therapy in patients with refractory ulcerative colitisAlimentary Pharmacology & Therapeutics, 2008
- Usefulness of quantitative real-time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapiesInflammatory Bowel Diseases, 2007
- Inflammatory bowel disease: clinical aspects and established and evolving therapiesThe Lancet, 2007
- Cytomegalovirus Infection in Patients with Ulcerative Colitis Diagnosed by Quantitative Real-Time PCR AnalysisDigestive Diseases and Sciences, 2006
- The Montreal classification of inflammatory bowel disease: controversies, consensus, and implicationsGut, 2006
- Long-term Outcome of Treatment with Intravenous Cyclosporin in Patients With Severe Ulcerative ColitisInflammatory Bowel Diseases, 2004
- FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics.The Journal of Antibiotics, 1987